Details of the Drug Combinations

General Information of This Drug (ID: DMGW1ID)

Drug Name
Sirolimus   DMGW1ID
Synonyms
53123-88-9; Rapamune; Rapamycin (Sirolimus); AY-22989; Rapammune; sirolimusum; WY-090217; RAPA; Antibiotic AY 22989; AY 22989; UNII-W36ZG6FT64; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; C51H79NO13; NSC 226080; DE-109; NCGC00021305-05; DSSTox_CID_3582; DSSTox_RID_77091; DSSTox_GSID_23582; Cypher; Supralimus; Wy 090217; Perceiva; RAP; RPM; Rapamycin from Streptomyces hygroscopicus; SIIA 9268A; LCP-Siro; MS-R001; Rapamune (TN); Rapamycin (TN); Sirolimus (RAPAMUNE); Rapamycin C-7, analog 4; Sirolimus (USAN/INN); Sirolimus [USAN:BAN:INN]; Sirolimus, Rapamune,Rapamycin; Heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy; 23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; 23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29; 3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Sirolimus (MTOR inhibitor)
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Brainstem neoplasm N.A. Approved [1]
Graft-versus-host disease 4B24 Approved [1]
Intracranial meningioma N.A. Approved [1]
Lung cancer 2C25.0 Approved [1]
Lung lymphangioleiomyomatosis N.A. Approved [1]
Lymphangioleiomyomatosis CB07 Approved [2]
Mucosal melanoma N.A. Approved [1]
Multiple myeloma 2A83 Approved [3]
Multiple sclerosis 8A40 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Organ transplant rejection NE84 Approved [4]
Plasma cell myeloma 2A83.1 Approved [1]
Prostate cancer 2C82.0 Approved [1]
Salivary gland squamous cell carcinoma N.A. Approved [1]
Uveitis 9A96.Z Phase 3 [5]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [6]
Dutch elm disease 8D64 Phase 1/2 [4]
Castration-resistant prostate carcinoma N.A. Investigative [1]
Neuroblastoma 2D11.2 Investigative [1]
Pancreatic acinar cell carcinoma N.A. Investigative [1]
Polycystic kidney disease GB8Y Investigative [1]
Rheumatoid arthritis FA20 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Immunosuppressive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

687 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Sirolimus DCRHQMW ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
ABIRATERONE + Sirolimus DCT44AK ABIRATERONE Anaplastic large cell lymphoma (Cell Line: SR) [7]
ABIRATERONE + Sirolimus DCLX2FC ABIRATERONE Astrocytoma (Cell Line: U251) [7]
ABIRATERONE + Sirolimus DCXJN9I ABIRATERONE Astrocytoma (Cell Line: SNB-19) [7]
ABIRATERONE + Sirolimus DCHQEWA ABIRATERONE Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
ABIRATERONE + Sirolimus DCI1M34 ABIRATERONE Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
ABIRATERONE + Sirolimus DCHII5R ABIRATERONE Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
ABIRATERONE + Sirolimus DC9MMQT ABIRATERONE Plasma cell myeloma (Cell Line: RPMI-8226) [7]
ABIRATERONE + Sirolimus DCSXYW4 ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [7]
ABIRATERONE + Sirolimus DC2C5DK ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
ABIRATERONE + Sirolimus DCF33KO ABIRATERONE Carcinoma (Cell Line: MCF7) [8]
ABIRATERONE + Sirolimus DC28YHQ ABIRATERONE Colon carcinoma (Cell Line: KM12) [8]
ABIRATERONE + Sirolimus DCJOVC6 ABIRATERONE Invasive ductal carcinoma (Cell Line: HS 578T) [8]
ABIRATERONE + Sirolimus DCFXF77 ABIRATERONE Adenocarcinoma (Cell Line: OVCAR3) [9]
ABIRATERONE + Sirolimus DCB8PHP ABIRATERONE Adenocarcinoma (Cell Line: A549) [9]
ABIRATERONE + Sirolimus DCGEUGE ABIRATERONE Adenocarcinoma (Cell Line: HT29) [9]
ABIRATERONE + Sirolimus DCWXSQC ABIRATERONE Adenocarcinoma (Cell Line: HCT116) [9]
ABIRATERONE + Sirolimus DCQKCAW ABIRATERONE Adenocarcinoma (Cell Line: HCC-2998) [9]
ABIRATERONE + Sirolimus DC0J3S4 ABIRATERONE Adenocarcinoma (Cell Line: HCT-15) [9]
ABIRATERONE + Sirolimus DCCGGT0 ABIRATERONE Adenocarcinoma (Cell Line: SW-620) [9]
ABIRATERONE + Sirolimus DC1LCIN ABIRATERONE Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
ABIRATERONE + Sirolimus DCZB25I ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
ABIRATERONE + Sirolimus DC0GRMS ABIRATERONE Large cell lung carcinoma (Cell Line: NCI-H460) [9]
ABIRATERONE + Sirolimus DCX7QV2 ABIRATERONE Lung adenocarcinoma (Cell Line: HOP-62) [9]
ABIRATERONE + Sirolimus DC3E7MM ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
ABIRATERONE + Sirolimus DC44BU7 ABIRATERONE Lung adenocarcinoma (Cell Line: NCI-H522) [9]
ABIRATERONE + Sirolimus DCDUCJA ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [9]
ABIRATERONE + Sirolimus DC2E5H6 ABIRATERONE Malignant melanoma (Cell Line: UACC62) [9]
ABIRATERONE + Sirolimus DCEH1XV ABIRATERONE Melanoma (Cell Line: MALME-3M) [9]
Amonafide + Sirolimus DC0JHX0 Amonafide Adenocarcinoma (Cell Line: NCIH23) [7]
Amonafide + Sirolimus DCYI2C6 Amonafide Adenocarcinoma (Cell Line: SW-620) [7]
Amonafide + Sirolimus DC0G6US Amonafide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Amonafide + Sirolimus DCK5Q3A Amonafide Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Anastrozole + Sirolimus DCPW5WD Anastrozole Adenocarcinoma (Cell Line: SW-620) [7]
Anastrozole + Sirolimus DCUVMQQ Anastrozole Amelanotic melanoma (Cell Line: M14) [7]
Anastrozole + Sirolimus DCOIC40 Anastrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [7]
Anastrozole + Sirolimus DCH0KTB Anastrozole Glioblastoma (Cell Line: SNB-75) [7]
Anastrozole + Sirolimus DCRG1N8 Anastrozole Glioma (Cell Line: SF-268) [7]
Arfolitixorin + Sirolimus DCSSKQE Arfolitixorin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
BIO-300 + Sirolimus DCDQTJU BIO-300 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
BIO-300 + Sirolimus DCP6HBX BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
BIO-300 + Sirolimus DCH7KTH BIO-300 Glioma (Cell Line: SF-539) [7]
BIO-300 + Sirolimus DCBWTVG BIO-300 Glioma (Cell Line: SF-268) [7]
BIO-300 + Sirolimus DC0LVD6 BIO-300 Colon adenocarcinoma (Cell Line: COLO 205) [8]
BIO-300 + Sirolimus DCT15VG BIO-300 Adenocarcinoma (Cell Line: SW-620) [9]
BIO-300 + Sirolimus DCF0A6T BIO-300 Amelanotic melanoma (Cell Line: M14) [9]
BIO-300 + Sirolimus DC1DK3X BIO-300 Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
BIO-300 + Sirolimus DCCAY37 BIO-300 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
BIO-300 + Sirolimus DC6UEVU BIO-300 Lung adenocarcinoma (Cell Line: HOP-62) [9]
BIO-300 + Sirolimus DCJ6TTC BIO-300 Melanoma (Cell Line: SK-MEL-2) [9]
Bleomycin + Sirolimus DCP2SWU Bleomycin Colon adenocarcinoma (Cell Line: COLO 205) [8]
Cabazitaxel + Sirolimus DC0THID Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [7]
Cabazitaxel + Sirolimus DCP73KR Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [7]
Cabazitaxel + Sirolimus DCQLNK0 Cabazitaxel Adenocarcinoma (Cell Line: A549) [7]
Cabazitaxel + Sirolimus DCNIOBO Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [7]
Cabazitaxel + Sirolimus DCAJVX3 Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [7]
Cabazitaxel + Sirolimus DC6C03Q Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [7]
Cabazitaxel + Sirolimus DC4K83U Cabazitaxel Adenocarcinoma (Cell Line: HT29) [7]
Cabazitaxel + Sirolimus DCVCLH7 Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Cabazitaxel + Sirolimus DCMHW3R Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Cabazitaxel + Sirolimus DC3V8NQ Cabazitaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Cabazitaxel + Sirolimus DCBG2ZH Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [7]
Cabazitaxel + Sirolimus DC25YED Cabazitaxel Astrocytoma (Cell Line: U251) [7]
Cabazitaxel + Sirolimus DCPLH16 Cabazitaxel Astrocytoma (Cell Line: SNB-19) [7]
Cabazitaxel + Sirolimus DCJ1VVO Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Cabazitaxel + Sirolimus DCDWMOT Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Cabazitaxel + Sirolimus DCHS59M Cabazitaxel Clear cell renal cell carcinoma (Cell Line: A498) [7]
Cabazitaxel + Sirolimus DCDEOE4 Cabazitaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [7]
Cabazitaxel + Sirolimus DC30CXZ Cabazitaxel Glioblastoma (Cell Line: SNB-75) [7]
Cabazitaxel + Sirolimus DC33X8K Cabazitaxel Glioma (Cell Line: SF-539) [7]
Cabazitaxel + Sirolimus DCG2KYM Cabazitaxel Glioma (Cell Line: SF-295) [7]
Cabazitaxel + Sirolimus DCC9FTL Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Cabazitaxel + Sirolimus DCWQ0Y2 Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [7]
Cabazitaxel + Sirolimus DC3SRH1 Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [7]
Cabazitaxel + Sirolimus DCK7A1Y Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Cabazitaxel + Sirolimus DCDAQNU Cabazitaxel Malignant melanoma (Cell Line: UACC62) [7]
Cabazitaxel + Sirolimus DCPAUWH Cabazitaxel Malignant melanoma (Cell Line: LOX IMVI) [7]
Cabazitaxel + Sirolimus DCEUVHD Cabazitaxel Melanoma (Cell Line: UACC-257) [7]
Cabazitaxel + Sirolimus DC5M5MZ Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Cabazitaxel + Sirolimus DCJMFP4 Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Cabazitaxel + Sirolimus DC3CG3E Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [7]
Cabazitaxel + Sirolimus DCX1O4W Cabazitaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [7]
Cabazitaxel + Sirolimus DCZMPRB Cabazitaxel Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Cabazitaxel + Sirolimus DCT4T79 Cabazitaxel Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Cabazitaxel + Sirolimus DCHR28Y Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [7]
Cabazitaxel + Sirolimus DCAFFM9 Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [7]
Cabazitaxel + Sirolimus DCDKG0V Cabazitaxel Renal cell carcinoma (Cell Line: UO-31) [7]
Cabazitaxel + Sirolimus DCVHIHW Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Cabazitaxel + Sirolimus DC2XSNE Cabazitaxel Carcinoma (Cell Line: RXF 393) [8]
Cabazitaxel + Sirolimus DC3JVOI Cabazitaxel Carcinoma (Cell Line: MCF7) [8]
Cabazitaxel + Sirolimus DCLAXWG Cabazitaxel Colon adenocarcinoma (Cell Line: COLO 205) [8]
Cabazitaxel + Sirolimus DC8WSO3 Cabazitaxel Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Cabazitaxel + Sirolimus DCSWP21 Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [8]
Cabazitaxel + Sirolimus DCITP4O Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [8]
Crizotinib + Sirolimus DCK02G8 Crizotinib Adenocarcinoma (Cell Line: DU-145) [7]
Crizotinib + Sirolimus DCKE0ZK Crizotinib Adenocarcinoma (Cell Line: NCIH23) [7]
Crizotinib + Sirolimus DCJJP8W Crizotinib Adenocarcinoma (Cell Line: HT29) [7]
Crizotinib + Sirolimus DCJZPSL Crizotinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Crizotinib + Sirolimus DCXTOM0 Crizotinib Amelanotic melanoma (Cell Line: MDA-MB-435) [7]
Crizotinib + Sirolimus DC42DMP Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [7]
Crizotinib + Sirolimus DCG7EWN Crizotinib Astrocytoma (Cell Line: SNB-19) [7]
Crizotinib + Sirolimus DCF3YRN Crizotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Crizotinib + Sirolimus DCXV5VW Crizotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Crizotinib + Sirolimus DC3TCN8 Crizotinib Clear cell renal cell carcinoma (Cell Line: A498) [7]
Crizotinib + Sirolimus DC5KXCY Crizotinib Glioma (Cell Line: SF-268) [7]
Crizotinib + Sirolimus DCV9LCM Crizotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [7]
Crizotinib + Sirolimus DCZOFJR Crizotinib Lung adenocarcinoma (Cell Line: EKVX) [7]
Crizotinib + Sirolimus DC8U72H Crizotinib Malignant melanoma (Cell Line: LOX IMVI) [7]
Crizotinib + Sirolimus DCILAWY Crizotinib Melanoma (Cell Line: SK-MEL-2) [7]
Crizotinib + Sirolimus DC47MFH Crizotinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Crizotinib + Sirolimus DCQ01A4 Crizotinib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Crizotinib + Sirolimus DCZ25C4 Crizotinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Crizotinib + Sirolimus DCTLRXZ Crizotinib Renal cell carcinoma (Cell Line: SN12C) [7]
Crizotinib + Sirolimus DCFMS3T Crizotinib Carcinoma (Cell Line: MCF7) [8]
Crizotinib + Sirolimus DCNNGD5 Crizotinib Colon carcinoma (Cell Line: KM12) [8]
Dacarbazine + Sirolimus DCTFXJP Dacarbazine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Dacarbazine + Sirolimus DCSTZZE Dacarbazine Colon adenocarcinoma (Cell Line: COLO 205) [8]
Dactinomycin + Sirolimus DCRP2M5 Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Dactinomycin + Sirolimus DC98VC4 Dactinomycin Carcinoma (Cell Line: RXF 393) [8]
Dactinomycin + Sirolimus DC0AA85 Dactinomycin Colon carcinoma (Cell Line: KM12) [8]
Dactinomycin + Sirolimus DCB7X37 Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Dactinomycin + Sirolimus DC3WWYZ Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [9]
Dactinomycin + Sirolimus DC98HCY Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [9]
Dactinomycin + Sirolimus DCFTXZQ Dactinomycin Adenocarcinoma (Cell Line: SW-620) [9]
Dactinomycin + Sirolimus DCLJREL Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [9]
Dactinomycin + Sirolimus DCX0XTX Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Dactinomycin + Sirolimus DC23QSG Dactinomycin Astrocytoma (Cell Line: U251) [9]
Dactinomycin + Sirolimus DCIEM4K Dactinomycin Astrocytoma (Cell Line: SNB-19) [9]
Dactinomycin + Sirolimus DCGPMZG Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [9]
Dactinomycin + Sirolimus DCW9QUD Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Dactinomycin + Sirolimus DC7NYBW Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [9]
Dactinomycin + Sirolimus DCNSQPZ Dactinomycin Glioblastoma (Cell Line: SNB-75) [9]
Dactinomycin + Sirolimus DCSBDX8 Dactinomycin Glioma (Cell Line: SF-539) [9]
Dactinomycin + Sirolimus DC9KVAF Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Dactinomycin + Sirolimus DCTPPE0 Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Dactinomycin + Sirolimus DCB5RLV Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Dactinomycin + Sirolimus DCYSNMT Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [9]
Dactinomycin + Sirolimus DCW1JBT Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [9]
Dactinomycin + Sirolimus DCW80PX Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [9]
Dactinomycin + Sirolimus DC5A3HK Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [9]
Dactinomycin + Sirolimus DCNGUIV Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Dactinomycin + Sirolimus DCCRW1K Dactinomycin Renal cell carcinoma (Cell Line: UO-31) [9]
Dexrazoxane + Sirolimus DC0V9MD Dexrazoxane Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Dexrazoxane + Sirolimus DCVN9WI Dexrazoxane Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Dexrazoxane + Sirolimus DCQBYNM Dexrazoxane Glioma (Cell Line: SF-268) [7]
Dexrazoxane + Sirolimus DC2DQJN Dexrazoxane Colon adenocarcinoma (Cell Line: COLO 205) [8]
Dexrazoxane + Sirolimus DCMXPMH Dexrazoxane Adenocarcinoma (Cell Line: NCIH23) [9]
DFN-15 + Sirolimus DCKCCAG DFN-15 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
DFN-15 + Sirolimus DCNBVS0 DFN-15 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
DFN-15 + Sirolimus DCGHVA0 DFN-15 Clear cell renal cell carcinoma (Cell Line: A498) [7]
DFN-15 + Sirolimus DC0UQNO DFN-15 Glioblastoma (Cell Line: SNB-75) [7]
DFN-15 + Sirolimus DC63B4X DFN-15 Glioma (Cell Line: SF-295) [7]
DFN-15 + Sirolimus DC1W97U DFN-15 Plasma cell myeloma (Cell Line: RPMI-8226) [7]
DFN-15 + Sirolimus DC5MX1Z DFN-15 Renal cell carcinoma (Cell Line: UO-31) [7]
DFN-15 + Sirolimus DCOZE9L DFN-15 Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
DFN-15 + Sirolimus DCA5U4K DFN-15 Carcinoma (Cell Line: MCF7) [8]
DFN-15 + Sirolimus DCNAHF7 DFN-15 Colon carcinoma (Cell Line: KM12) [8]
DFN-15 + Sirolimus DCI0SEP DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [8]
DFN-15 + Sirolimus DCF8BBO DFN-15 Invasive ductal carcinoma (Cell Line: T-47D) [8]
DFN-15 + Sirolimus DC1H5CM DFN-15 Adenocarcinoma (Cell Line: OVCAR3) [9]
DFN-15 + Sirolimus DC8I10T DFN-15 Adenocarcinoma (Cell Line: A549) [9]
DFN-15 + Sirolimus DCAL6WM DFN-15 Adenocarcinoma (Cell Line: HCT116) [9]
DFN-15 + Sirolimus DC9IFZH DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
DFN-15 + Sirolimus DCFUNWZ DFN-15 Lung adenocarcinoma (Cell Line: NCI-H522) [9]
DFN-15 + Sirolimus DC7Q7JB DFN-15 Malignant melanoma (Cell Line: LOX IMVI) [9]
DFN-15 + Sirolimus DCS61SG DFN-15 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Digitoxin + Sirolimus DC7SLLH Digitoxin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Epirubicin + Sirolimus DC88J3K Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Epirubicin + Sirolimus DCEZF6A Epirubicin Renal cell carcinoma (Cell Line: UO-31) [7]
Epirubicin + Sirolimus DCJI1QX Epirubicin Colon carcinoma (Cell Line: KM12) [8]
Epirubicin + Sirolimus DC71ZJU Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Epirubicin + Sirolimus DCY8TBC Epirubicin Adenocarcinoma (Cell Line: A549) [9]
Epirubicin + Sirolimus DCYOHV0 Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [9]
Epirubicin + Sirolimus DCZYKOF Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [9]
Estramustine + Sirolimus DCIGSJ6 Estramustine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Estramustine + Sirolimus DC0O9HS Estramustine Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Fludarabine + Sirolimus DCT0521 Fludarabine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Fludarabine + Sirolimus DCLEJ1S Fludarabine Adenocarcinoma (Cell Line: HCT116) [9]
Fludarabine + Sirolimus DCWSK7Z Fludarabine Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Fludarabine + Sirolimus DCVQ4H2 Fludarabine Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Gefitinib + Sirolimus DCD2KPZ Gefitinib Adenocarcinoma (Cell Line: DU-145) [7]
Gefitinib + Sirolimus DCVBPGY Gefitinib Adenocarcinoma (Cell Line: NCIH23) [7]
Gefitinib + Sirolimus DCCIEJ0 Gefitinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Gefitinib + Sirolimus DCV7YR5 Gefitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Gefitinib + Sirolimus DC0Z9JC Gefitinib Amelanotic melanoma (Cell Line: M14) [7]
Gefitinib + Sirolimus DCOB0HA Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [7]
Gefitinib + Sirolimus DCLJ3AG Gefitinib Melanoma (Cell Line: MALME-3M) [7]
Gefitinib + Sirolimus DC31ULJ Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [7]
Gefitinib + Sirolimus DC5ZN0Z Gefitinib Colon adenocarcinoma (Cell Line: COLO 205) [8]
Hepzato + Sirolimus DCRT630 Hepzato Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Hepzato + Sirolimus DCYBFGY Hepzato Adenocarcinoma (Cell Line: HCC-2998) [9]
Hepzato + Sirolimus DCIW07V Hepzato Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Idarubicin + Sirolimus DCQ095Z Idarubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Idarubicin + Sirolimus DCG0JWO Idarubicin Glioma (Cell Line: SF-539) [7]
Imatinib + Sirolimus DC6STGW Imatinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Imatinib + Sirolimus DCXDO0X Imatinib Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Indazole derivative 5 + Sirolimus DCLZRYB Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Indazole derivative 5 + Sirolimus DC2QVWT Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [7]
Indazole derivative 5 + Sirolimus DC4EHKI Indazole derivative 5 Astrocytoma (Cell Line: SNB-19) [7]
Indazole derivative 5 + Sirolimus DC8UTUK Indazole derivative 5 Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Indazole derivative 5 + Sirolimus DCM7XAP Indazole derivative 5 Chronic myelogenous leukemia (Cell Line: K-562) [7]
Indazole derivative 5 + Sirolimus DCS49OY Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Indazole derivative 5 + Sirolimus DC0N2CW Indazole derivative 5 Glioblastoma (Cell Line: SNB-75) [7]
Indazole derivative 5 + Sirolimus DCYYZEK Indazole derivative 5 Renal cell carcinoma (Cell Line: SN12C) [7]
Indazole derivative 5 + Sirolimus DCGWKZT Indazole derivative 5 Colon carcinoma (Cell Line: KM12) [8]
Indazole derivative 5 + Sirolimus DC5HXWA Indazole derivative 5 Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Indazole derivative 5 + Sirolimus DCRCP1F Indazole derivative 5 Adenocarcinoma (Cell Line: A549) [9]
Indazole derivative 5 + Sirolimus DCMSSP4 Indazole derivative 5 Adenocarcinoma (Cell Line: HCT-15) [9]
Indazole derivative 5 + Sirolimus DC9FMWN Indazole derivative 5 Adenocarcinoma (Cell Line: HCC-2998) [9]
Indazole derivative 5 + Sirolimus DC6RD8W Indazole derivative 5 Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Indazole derivative 5 + Sirolimus DCIT16C Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Indazole derivative 5 + Sirolimus DC5JY5X Indazole derivative 5 Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Indazole derivative 5 + Sirolimus DC8J74F Indazole derivative 5 Malignant melanoma (Cell Line: LOX IMVI) [9]
Indazole derivative 5 + Sirolimus DCH9UPD Indazole derivative 5 Malignant melanoma (Cell Line: UACC62) [9]
Letrozole + Sirolimus DC4MYEK Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Letrozole + Sirolimus DCNBP7W Letrozole High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [7]
Letrozole + Sirolimus DC4DE81 Letrozole Plasma cell myeloma (Cell Line: RPMI-8226) [7]
LIAROZOLE + Sirolimus DCZ4JHV LIAROZOLE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
LIAROZOLE + Sirolimus DCRC9UZ LIAROZOLE Astrocytoma (Cell Line: SNB-19) [7]
LIAROZOLE + Sirolimus DCJKKG0 LIAROZOLE Glioma (Cell Line: SF-295) [7]
LIAROZOLE + Sirolimus DCHLSC9 LIAROZOLE Colon adenocarcinoma (Cell Line: COLO 205) [8]
LIAROZOLE + Sirolimus DCFVQYW LIAROZOLE Invasive ductal carcinoma (Cell Line: T-47D) [8]
LIAROZOLE + Sirolimus DCR7DEB LIAROZOLE Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Methotrexate + Sirolimus DCJ5VCR Methotrexate Adenocarcinoma (Cell Line: HCT116) [7]
Methotrexate + Sirolimus DCOYJV1 Methotrexate Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Nilotinib + Sirolimus DCL8R1N Nilotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Nilotinib + Sirolimus DC1ENA6 Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [7]
Nilotinib + Sirolimus DC8TLTV Nilotinib Clear cell renal cell carcinoma (Cell Line: A498) [7]
Nilotinib + Sirolimus DC58CJA Nilotinib Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Nilotinib + Sirolimus DCKKVP9 Nilotinib Adenocarcinoma (Cell Line: OVCAR3) [9]
Plicamycin + Sirolimus DC293BQ Plicamycin Astrocytoma (Cell Line: U251) [7]
Plicamycin + Sirolimus DC4JTGU Plicamycin Glioma (Cell Line: SF-539) [7]
Plicamycin + Sirolimus DC3CFFS Plicamycin Glioma (Cell Line: SF-268) [7]
Plicamycin + Sirolimus DCCBX8F Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Plicamycin + Sirolimus DCX7L08 Plicamycin Renal cell carcinoma (Cell Line: UO-31) [7]
Plicamycin + Sirolimus DC733JO Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Plicamycin + Sirolimus DCR5UCP Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Plicamycin + Sirolimus DCOGK6P Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Plicamycin + Sirolimus DCE2WCT Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Plicamycin + Sirolimus DCG4464 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [9]
Plicamycin + Sirolimus DCPGRHR Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Plicamycin + Sirolimus DCLSJIB Plicamycin Prostate carcinoma (Cell Line: PC-3) [9]
Raloxifene + Sirolimus DCE7071 Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Raloxifene + Sirolimus DCD29OF Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Raloxifene + Sirolimus DCZRYFU Raloxifene Carcinoma (Cell Line: MCF7) [8]
Ruxolitinib + Sirolimus DCJEEHT Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Ruxolitinib + Sirolimus DCRF3F9 Ruxolitinib Anaplastic large cell lymphoma (Cell Line: SR) [7]
Ruxolitinib + Sirolimus DC3SOIJ Ruxolitinib Chronic myelogenous leukemia (Cell Line: K-562) [7]
Ruxolitinib + Sirolimus DCB8TRZ Ruxolitinib Clear cell renal cell carcinoma (Cell Line: A498) [7]
Ruxolitinib + Sirolimus DC8V49W Ruxolitinib Renal cell carcinoma (Cell Line: UO-31) [7]
Ruxolitinib + Sirolimus DC3Y9K7 Ruxolitinib Carcinoma (Cell Line: RXF 393) [8]
Ruxolitinib + Sirolimus DCA2R9L Ruxolitinib Carcinoma (Cell Line: MCF7) [8]
Ruxolitinib + Sirolimus DCSQ5N2 Ruxolitinib Colon carcinoma (Cell Line: KM12) [8]
Ruxolitinib + Sirolimus DCGLT6F Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Ruxolitinib + Sirolimus DCRCWM0 Ruxolitinib Adenocarcinoma (Cell Line: DU-145) [9]
Ruxolitinib + Sirolimus DC9CBB5 Ruxolitinib Adenocarcinoma (Cell Line: NCIH23) [9]
Ruxolitinib + Sirolimus DC9H5GM Ruxolitinib Adenocarcinoma (Cell Line: A549) [9]
Ruxolitinib + Sirolimus DC72H01 Ruxolitinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Ruxolitinib + Sirolimus DCI76Z1 Ruxolitinib Malignant melanoma (Cell Line: LOX IMVI) [9]
Ruxolitinib + Sirolimus DC7GGFF Ruxolitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Ruxolitinib + Sirolimus DCLCDII Ruxolitinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Sirolimus + Fulvestrant DC2BZ36 Fulvestrant Glioma (Cell Line: SF-268) [7]
Sirolimus + Ixabepilone DC61FG7 Ixabepilone Glioma (Cell Line: SF-268) [7]
Sirolimus + Lapatinib DCCMSKL Lapatinib Anaplastic large cell lymphoma (Cell Line: SR) [7]
Sirolimus + Lapatinib DCX6X2A Lapatinib Astrocytoma (Cell Line: SNB-19) [7]
Sirolimus + Lapatinib DC81Q64 Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Lapatinib DC8DFRJ Lapatinib Clear cell renal cell carcinoma (Cell Line: A498) [7]
Sirolimus + Lapatinib DCKVHNO Lapatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Sirolimus + Lapatinib DCC5VXQ Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Sirolimus + Lapatinib DCHH364 Lapatinib Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Sirolimus + Lapatinib DCXOLH6 Lapatinib Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Sirolimus + Lapatinib DC9AMY8 Lapatinib Renal cell carcinoma (Cell Line: UO-31) [7]
Sirolimus + PMID28460551-Compound-2 DCR9UN2 PMID28460551-Compound-2 Astrocytoma (Cell Line: U251) [7]
Sirolimus + PMID28460551-Compound-2 DC4PEYH PMID28460551-Compound-2 Renal cell carcinoma (Cell Line: UO-31) [7]
Sirolimus + Cyclophosphamide DCA7OGK Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Sirolimus + Methotrexate DCM9CYL Methotrexate Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Sirolimus + Methotrexate DCR7109 Methotrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Sirolimus + Arsenic trioxide DC1EMRK Arsenic trioxide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Sirolimus + Arsenic trioxide DC5F1Z6 Arsenic trioxide Clear cell renal cell carcinoma (Cell Line: A498) [7]
Sirolimus + Arsenic trioxide DC1MCVN Arsenic trioxide Glioblastoma (Cell Line: SNB-75) [7]
Sirolimus + Arsenic trioxide DC3QU7Y Arsenic trioxide Renal cell carcinoma (Cell Line: SN12C) [7]
Sirolimus + Topetecan DCKSZ9Q Topetecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Sirolimus + Topetecan DCT1F3L Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [7]
Sirolimus + Topetecan DCEIK43 Topetecan Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Sirolimus + Topetecan DC9BF15 Topetecan Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Topetecan DCQRGX8 Topetecan Glioma (Cell Line: SF-268) [7]
Sirolimus + Pralatrexate DC0ZTXE Pralatrexate Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Sirolimus + Pralatrexate DCB1DNK Pralatrexate Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Pralatrexate DCM7YNL Pralatrexate Glioma (Cell Line: SF-539) [7]
Sirolimus + Terameprocol DCSPGGO Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Terameprocol DCC3EAT Terameprocol Clear cell renal cell carcinoma (Cell Line: A498) [7]
Sirolimus + Terameprocol DCWY3GX Terameprocol Glioma (Cell Line: SF-539) [7]
Sirolimus + Terameprocol DCKZ4GY Terameprocol Glioma (Cell Line: SF-295) [7]
Sirolimus + Ifosfamide DCUQ49T Ifosfamide Renal cell carcinoma (Cell Line: SN12C) [7]
Sirolimus + Docetaxel DCWA53B Docetaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Sirolimus + Docetaxel DCJSDSY Docetaxel Astrocytoma (Cell Line: U251) [7]
Sirolimus + Docetaxel DCBSFSP Docetaxel Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Docetaxel DCXKPNV Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [7]
Sirolimus + Docetaxel DCYYZIW Docetaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Sirolimus + Mitomycin DCYSF5I Mitomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Sirolimus + Mitomycin DCPZVWJ Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [7]
Sirolimus + Mitomycin DCPETSV Mitomycin Glioma (Cell Line: SF-295) [7]
Sirolimus + TEM DCIBWUJ TEM Astrocytoma (Cell Line: U251) [7]
Sirolimus + TEM DCTXNYM TEM Astrocytoma (Cell Line: SNB-19) [7]
Sirolimus + Bleomycin DCFFN30 Bleomycin Anaplastic large cell lymphoma (Cell Line: SR) [7]
Sirolimus + Bortezomib DC64R81 Bortezomib Glioma (Cell Line: SF-539) [7]
Sirolimus + Valrubicin DCCVTMP Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Sirolimus + Valrubicin DCJO842 Valrubicin Glioblastoma (Cell Line: SNB-75) [7]
Sirolimus + Cisplatin DC8ABAP Cisplatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Sirolimus + Cisplatin DCAL12A Cisplatin Glioma (Cell Line: SF-539) [7]
Sirolimus + Chlorambucil DCDY1H4 Chlorambucil Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Sirolimus + Chlorambucil DC2ZB4F Chlorambucil Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Sirolimus + Sorafenib DCXR7M3 Sorafenib Glioblastoma (Cell Line: SNB-75) [7]
Sirolimus + Azacitidine DCZAVVA Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [7]
Sirolimus + Azacitidine DC85V20 Azacitidine Chronic myelogenous leukemia (Cell Line: K-562) [7]
Sirolimus + Azacitidine DCOG0CU Azacitidine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Sirolimus + Vinflunine DCFLKBO Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Sirolimus + Vinflunine DCTCS9L Vinflunine Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Sirolimus + Taxol DCH0Y3V Taxol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Sirolimus + Taxol DC8HHAD Taxol Astrocytoma (Cell Line: U251) [7]
Sirolimus + Taxol DCY7BQO Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Sirolimus + Taxol DC00QAS Taxol Glioma (Cell Line: SF-539) [7]
Sirolimus + Taxol DCBBPMX Taxol Renal cell carcinoma (Cell Line: UO-31) [7]
Sirolimus + FORMESTANE DCH2YP8 FORMESTANE Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Sirolimus + FORMESTANE DCPIZM8 FORMESTANE Glioma (Cell Line: SF-268) [7]
Sirolimus + Aminolevulinic Acid Hydrochloride DCG8C0E Aminolevulinic Acid Hydrochloride Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Sirolimus + Dasatinib DCLCMPI Dasatinib Astrocytoma (Cell Line: U251) [7]
Sirolimus + Dasatinib DC8UM98 Dasatinib Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Sirolimus + Dasatinib DCB3ZKI Dasatinib Clear cell renal cell carcinoma (Cell Line: A498) [7]
Sirolimus + Fulvestrant DC0MZT9 Fulvestrant Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Ixabepilone DCW9IWU Ixabepilone Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Sirolimus + Ixabepilone DC4Z39Y Ixabepilone Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + Lapatinib DCUR8MW Lapatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Sirolimus + Lapatinib DCMO56E Lapatinib Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Lapatinib DCDD7CT Lapatinib Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + Lapatinib DCWZ6D1 Lapatinib Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Sirolimus + Lapatinib DC0KKYA Lapatinib Invasive ductal carcinoma (Cell Line: BT-549) [8]
Sirolimus + Methotrexate DCLB87L Methotrexate Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Arsenic trioxide DCLRLZT Arsenic trioxide Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Topetecan DCUT4OC Topetecan Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Topetecan DCH8LB6 Topetecan Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Terameprocol DC03ATX Terameprocol Carcinoma (Cell Line: MCF7) [8]
Sirolimus + Terameprocol DCH6Y5W Terameprocol Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + Terameprocol DCBLKPP Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Ifosfamide DCXBLDW Ifosfamide Carcinoma (Cell Line: RXF 393) [8]
Sirolimus + Ifosfamide DCWW0MZ Ifosfamide Invasive ductal carcinoma (Cell Line: BT-549) [8]
Sirolimus + Docetaxel DC1PSUA Docetaxel Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Docetaxel DCF70NK Docetaxel Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + Docetaxel DCBTY2J Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + Mitomycin DC4QS9O Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Sirolimus + Mitomycin DCUF6NO Mitomycin Invasive ductal carcinoma (Cell Line: BT-549) [8]
Sirolimus + Altretamine DCVBZBI Altretamine Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Altretamine DCXNBUZ Altretamine Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + TEM DC7DEDD TEM Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + TEM DCHUZA7 TEM Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + TEM DC0FH7P TEM Invasive ductal carcinoma (Cell Line: T-47D) [8]
Sirolimus + TEM DC7V6RP TEM Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Sirolimus + Bortezomib DCWKHVR Bortezomib Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Valrubicin DCG520H Valrubicin Carcinoma (Cell Line: RXF 393) [8]
Sirolimus + Valrubicin DCCR4QT Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [8]
Sirolimus + Sorafenib DCXIIEC Sorafenib Carcinoma (Cell Line: MCF7) [8]
Sirolimus + Sorafenib DCNC6MS Sorafenib Invasive ductal carcinoma (Cell Line: BT-549) [8]
Sirolimus + Romidepsin DC7WGIC Romidepsin Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Sirolimus + Azacitidine DC4SD6F Azacitidine Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + Vinflunine DCUD87H Vinflunine Carcinoma (Cell Line: MCF7) [8]
Sirolimus + Taxol DCUFNAI Taxol Colon adenocarcinoma (Cell Line: COLO 205) [8]
Sirolimus + Taxol DCBTOIF Taxol Colon carcinoma (Cell Line: KM12) [8]
Sirolimus + FORMESTANE DCI3SR0 FORMESTANE Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Sirolimus + Dasatinib DCKZF7N Dasatinib Carcinoma (Cell Line: RXF 393) [8]
Sirolimus + Pentostatin DCYC368 Pentostatin Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Fulvestrant DCUT9KF Fulvestrant Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Sirolimus + Fulvestrant DCL8VMH Fulvestrant Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Fulvestrant DCEU5R1 Fulvestrant Malignant melanoma (Cell Line: LOX IMVI) [9]
Sirolimus + Ixabepilone DCRQ515 Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
Sirolimus + Ixabepilone DC3NB7A Ixabepilone Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + Ixabepilone DCPAOTX Ixabepilone Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Lapatinib DCU1ARS Lapatinib Adenocarcinoma (Cell Line: DU-145) [9]
Sirolimus + Lapatinib DCVR78D Lapatinib Adenocarcinoma (Cell Line: OVCAR3) [9]
Sirolimus + Lapatinib DCQPO9W Lapatinib Adenocarcinoma (Cell Line: NCIH23) [9]
Sirolimus + Lapatinib DC2T1AX Lapatinib Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Lapatinib DC8LNN6 Lapatinib Adenocarcinoma (Cell Line: SW-620) [9]
Sirolimus + Lapatinib DCS4QIF Lapatinib Adenocarcinoma (Cell Line: HCC-2998) [9]
Sirolimus + Lapatinib DCVYQDD Lapatinib Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Lapatinib DC3ONFW Lapatinib Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Lapatinib DCS8OSN Lapatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
Sirolimus + Lapatinib DCA0IKM Lapatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Sirolimus + Lapatinib DCLV9UI Lapatinib Lung adenocarcinoma (Cell Line: EKVX) [9]
Sirolimus + Lapatinib DC32URJ Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Sirolimus + Lapatinib DCPHZ5A Lapatinib Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Methotrexate DCK25CW Methotrexate Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Methotrexate DCNIBDF Methotrexate Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + Methotrexate DCRH0M1 Methotrexate Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Methotrexate DCKKDR1 Methotrexate Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Arsenic trioxide DCDRB5E Arsenic trioxide Amelanotic melanoma (Cell Line: M14) [9]
Sirolimus + Arsenic trioxide DCSRV4W Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + Arsenic trioxide DCSQTXM Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [9]
Sirolimus + Arsenic trioxide DCFTQC8 Arsenic trioxide Lung adenocarcinoma (Cell Line: HOP-62) [9]
Sirolimus + Arsenic trioxide DCBDNQ8 Arsenic trioxide Lung adenocarcinoma (Cell Line: EKVX) [9]
Sirolimus + Arsenic trioxide DCC68GG Arsenic trioxide Melanoma (Cell Line: MALME-3M) [9]
Sirolimus + Arsenic trioxide DCE5AJS Arsenic trioxide Melanoma (Cell Line: UACC-257) [9]
Sirolimus + Arsenic trioxide DCF8OCK Arsenic trioxide Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Topetecan DCDYWWH Topetecan Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Topetecan DCYZVQZ Topetecan Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Pralatrexate DC48KUV Pralatrexate Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Pralatrexate DCN5NUN Pralatrexate Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Terameprocol DC9CTJ7 Terameprocol Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Terameprocol DCUOZAI Terameprocol Amelanotic melanoma (Cell Line: M14) [9]
Sirolimus + Terameprocol DCICKFD Terameprocol Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + SCH 727965 DCBTP44 SCH 727965 Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + SCH 727965 DCRWP21 SCH 727965 Adenocarcinoma (Cell Line: HT29) [9]
Sirolimus + SCH 727965 DC1VM81 SCH 727965 Adenocarcinoma (Cell Line: HCC-2998) [9]
Sirolimus + Ifosfamide DCRX0PF Ifosfamide Adenocarcinoma (Cell Line: SW-620) [9]
Sirolimus + Ifosfamide DCK6IKW Ifosfamide Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Sirolimus + Docetaxel DCOW7RM Docetaxel Adenocarcinoma (Cell Line: DU-145) [9]
Sirolimus + Docetaxel DCLK7PY Docetaxel Adenocarcinoma (Cell Line: OVCAR3) [9]
Sirolimus + Docetaxel DCY02V0 Docetaxel Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Docetaxel DC8ZNH5 Docetaxel Adenocarcinoma (Cell Line: HT29) [9]
Sirolimus + Docetaxel DC845ZU Docetaxel Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Docetaxel DCMZYRP Docetaxel Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Sirolimus + Docetaxel DCW5LD9 Docetaxel Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + Docetaxel DC6ZYWG Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Sirolimus + Docetaxel DCHFDIF Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Sirolimus + Docetaxel DCZGZWG Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Sirolimus + Docetaxel DCZ986H Docetaxel Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Docetaxel DCEZJCM Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [9]
Sirolimus + Docetaxel DCQ0IS4 Docetaxel Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Bendamustine hydrochloride DCA06DW Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Bendamustine hydrochloride DCJY3GB Bendamustine hydrochloride Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Sirolimus + Mitomycin DCDUCZ0 Mitomycin Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Mitomycin DCV2UA1 Mitomycin Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Mitomycin DCZWROF Mitomycin Adenocarcinoma (Cell Line: SW-620) [9]
Sirolimus + Mitomycin DC57QFS Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Sirolimus + Mitomycin DC8JGN9 Mitomycin Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Mitomycin DCF3MU7 Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Sirolimus + Mitomycin DC4OATE Mitomycin Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Altretamine DCQRF6C Altretamine Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Altretamine DCJ0R2V Altretamine Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + TEM DCMI4P2 TEM Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + TEM DCWQUW4 TEM Adenocarcinoma (Cell Line: HT29) [9]
Sirolimus + TEM DCEG8YH TEM Melanoma (Cell Line: UACC-257) [9]
Sirolimus + TEM DCP7CLB TEM Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Bleomycin DCAMOY2 Bleomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + Bleomycin DCBFVD1 Bleomycin Melanoma (Cell Line: UACC-257) [9]
Sirolimus + Bortezomib DCQZA6K Bortezomib Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Bortezomib DC3RZWZ Bortezomib Adenocarcinoma (Cell Line: SW-620) [9]
Sirolimus + Bortezomib DC0INCX Bortezomib Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Bortezomib DCFE3Y9 Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Sirolimus + Bortezomib DC0QYOQ Bortezomib Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Sirolimus + Bortezomib DCZW8RL Bortezomib Melanoma (Cell Line: UACC-257) [9]
Sirolimus + Valrubicin DCE7YV4 Valrubicin Adenocarcinoma (Cell Line: OVCAR3) [9]
Sirolimus + Valrubicin DCBP3RP Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Sirolimus + Valrubicin DCNMBPY Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [9]
Sirolimus + Valrubicin DCXT7RI Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [9]
Sirolimus + Valrubicin DC0ODXH Valrubicin Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Cisplatin DC102KS Cisplatin Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Cisplatin DCU4UY7 Cisplatin Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Sirolimus + Cisplatin DCOUWAR Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [9]
Sirolimus + Chlorambucil DCHE2VZ Chlorambucil Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Sirolimus + Sorafenib DCR8MJA Sorafenib Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Sorafenib DC1PBBG Sorafenib Melanoma (Cell Line: SK-MEL-2) [9]
Sirolimus + Sorafenib DCBBI5V Sorafenib Melanoma (Cell Line: UACC-257) [9]
Sirolimus + Sorafenib DCBK8YL Sorafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Sirolimus + Sorafenib DCHI6AE Sorafenib Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + ER819762 DC0POUY ER819762 Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Sirolimus + Romidepsin DCAXN2S Romidepsin Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Sirolimus + Azacitidine DCFOPTM Azacitidine Adenocarcinoma (Cell Line: DU-145) [9]
Sirolimus + Pomalidomide DCRUJ8J Pomalidomide Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Vinflunine DCF7R4C Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [9]
Sirolimus + Vinflunine DCNDBSM Vinflunine Adenocarcinoma (Cell Line: HCT-15) [9]
Sirolimus + Vinflunine DC48FB0 Vinflunine Adenocarcinoma (Cell Line: SW-620) [9]
Sirolimus + Vinflunine DCNZR44 Vinflunine Lung adenocarcinoma (Cell Line: HOP-62) [9]
Sirolimus + Vinflunine DCIP2WD Vinflunine Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Sirolimus + Vinflunine DCQD0GW Vinflunine Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + Vinflunine DCYH1N4 Vinflunine Malignant melanoma (Cell Line: LOX IMVI) [9]
Sirolimus + Vinflunine DCLIY5K Vinflunine Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Sirolimus + Vinflunine DCQUQ8L Vinflunine Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Mercaptopurine DC38MZJ Mercaptopurine Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Sirolimus + Taxol DCEKHM8 Taxol Adenocarcinoma (Cell Line: OVCAR3) [9]
Sirolimus + Taxol DCT7GMB Taxol Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + Taxol DCSJH1I Taxol Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
Sirolimus + Taxol DCIRFB0 Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Sirolimus + Taxol DCRTI8O Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Sirolimus + Taxol DCG1VQV Taxol Malignant melanoma (Cell Line: LOX IMVI) [9]
Sirolimus + Taxol DCTSNDQ Taxol Melanoma (Cell Line: MALME-3M) [9]
Sirolimus + Taxol DCZWOXB Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Sirolimus + Taxol DCTGG31 Taxol Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + PMID28870136-Compound-43 DCROL3T PMID28870136-Compound-43 Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Sirolimus + FORMESTANE DCQBNI8 FORMESTANE Adenocarcinoma (Cell Line: A549) [9]
Sirolimus + FORMESTANE DCWFSE8 FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Sirolimus + FORMESTANE DCFMSDH FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Sirolimus + FORMESTANE DCGG62H FORMESTANE Malignant melanoma (Cell Line: UACC62) [9]
Sirolimus + FORMESTANE DCJ7KCY FORMESTANE Melanoma (Cell Line: MALME-3M) [9]
Sirolimus + FORMESTANE DCMM3JL FORMESTANE Prostate carcinoma (Cell Line: PC-3) [9]
Sirolimus + Aminolevulinic Acid Hydrochloride DCKS8CX Aminolevulinic Acid Hydrochloride Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Aminolevulinic Acid Hydrochloride DCXUGM4 Aminolevulinic Acid Hydrochloride Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Sirolimus + Busulfan DCVQGER Busulfan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Sirolimus + Busulfan DCVAPHW Busulfan Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Sirolimus + Dasatinib DC2IGLM Dasatinib Adenocarcinoma (Cell Line: HCT116) [9]
Sirolimus + Dasatinib DC9L277 Dasatinib Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
Sirolimus + Dasatinib DCG8TAD Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Sirolimus + Panobinostat DCVE79H Panobinostat Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [7]
Sirolimus + Acalabrutinib DC74571 Acalabrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [7]
Sirolimus + Idarubicin DCOUAVK Idarubicin Glioblastoma? (Cell Line: T98G) [7]
Sirolimus + Ibrutinib DCC6ERM Ibrutinib Diffuse large B cell lymphoma (Cell Line: TMD8) [7]
Sirolimus + Ruxolitinib DCFWIW4 Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [9]
Sirolimus + Ruxolitinib DCXE2HE Ruxolitinib Hodgkin lymphoma (Cell Line: HDLM-2) [9]
SY-1425 + Sirolimus DCVYDUM SY-1425 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
SY-1425 + Sirolimus DCBCE1A SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [7]
SY-1425 + Sirolimus DCND9UY SY-1425 Clear cell renal cell carcinoma (Cell Line: A498) [7]
SY-1425 + Sirolimus DC3IJWZ SY-1425 Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
SY-1425 + Sirolimus DC8E3D4 SY-1425 Glioma (Cell Line: SF-295) [7]
SY-1425 + Sirolimus DC06STC SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [7]
SY-1425 + Sirolimus DC12XZ9 SY-1425 Renal cell carcinoma (Cell Line: UO-31) [7]
SY-1425 + Sirolimus DCV2VN6 SY-1425 Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
SY-1425 + Sirolimus DCCRUIC SY-1425 Invasive ductal carcinoma (Cell Line: HS 578T) [8]
SY-1425 + Sirolimus DCU3MGL SY-1425 Invasive ductal carcinoma (Cell Line: T-47D) [8]
SY-1425 + Sirolimus DCY694H SY-1425 Adenocarcinoma (Cell Line: A549) [9]
SY-1425 + Sirolimus DCD2356 SY-1425 Adenocarcinoma (Cell Line: HCT116) [9]
SY-1425 + Sirolimus DCQU3BW SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [9]
SY-1425 + Sirolimus DC1UB77 SY-1425 Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
SY-1425 + Sirolimus DCHHGA9 SY-1425 Melanoma (Cell Line: MALME-3M) [9]
SY-1425 + Sirolimus DC7BZYP SY-1425 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Terameprocol + Sirolimus DCQOQM3 Terameprocol Astrocytoma (Cell Line: U251) [7]
Terameprocol + Sirolimus DCE0S6Y Terameprocol Chronic myelogenous leukemia (Cell Line: K-562) [7]
Terameprocol + Sirolimus DCJFIHB Terameprocol Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Terameprocol + Sirolimus DCQRKBN Terameprocol Clear cell renal cell carcinoma (Cell Line: A498) [7]
Terameprocol + Sirolimus DC6A2KO Terameprocol Glioma (Cell Line: SF-539) [7]
Terameprocol + Sirolimus DCXJONC Terameprocol Glioma (Cell Line: SF-295) [7]
Terameprocol + Sirolimus DCIGCS2 Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Terameprocol + Sirolimus DC738Y5 Terameprocol Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Terameprocol + Sirolimus DCS3T3G Terameprocol Colon carcinoma (Cell Line: KM12) [8]
Terameprocol + Sirolimus DCZQKB4 Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [8]
Terameprocol + Sirolimus DCI81PE Terameprocol Adenocarcinoma (Cell Line: HCT116) [9]
Terameprocol + Sirolimus DCDBVY7 Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Terameprocol + Sirolimus DC4J52P Terameprocol Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Terameprocol + Sirolimus DCHKN0L Terameprocol Lung adenocarcinoma (Cell Line: EKVX) [9]
Terameprocol + Sirolimus DCRRST1 Terameprocol Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Terameprocol + Sirolimus DCSMHQ0 Terameprocol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Thioguanine + Sirolimus DCXEQH0 Thioguanine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Thioguanine + Sirolimus DC51ICH Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Thioguanine + Sirolimus DC14BY5 Thioguanine Colon adenocarcinoma (Cell Line: COLO 205) [8]
Thioguanine + Sirolimus DCTP44V Thioguanine Amelanotic melanoma (Cell Line: M14) [9]
Topotecan + Sirolimus DCM6UL6 Topotecan Amelanotic melanoma (Cell Line: M14) [9]
Topotecan + Sirolimus DCYKTGD Topotecan Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Topotecan + Sirolimus DCWP6H1 Topotecan Glioma (Cell Line: SF-268) [9]
Topotecan + Sirolimus DCRRPLX Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Triapine + Sirolimus DCRGVLE Triapine Carcinoma (Cell Line: RXF 393) [8]
Triapine + Sirolimus DCR6XHE Triapine Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Trifluridine + Sirolimus DC54LBB Trifluridine Colon adenocarcinoma (Cell Line: COLO 205) [8]
Uracil mustard + Sirolimus DCF6J1C Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Uracil mustard + Sirolimus DCBIUTL Uracil mustard Glioma (Cell Line: SF-268) [7]
Uracil mustard + Sirolimus DCUNJI5 Uracil mustard Colon adenocarcinoma (Cell Line: COLO 205) [8]
Uracil mustard + Sirolimus DCHN0M2 Uracil mustard Melanoma (Cell Line: SK-MEL-2) [9]
Valrubicin + Sirolimus DCJWEPB Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [7]
Valrubicin + Sirolimus DCQF0G8 Valrubicin Anaplastic large cell lymphoma (Cell Line: SR) [7]
Valrubicin + Sirolimus DCIWRID Valrubicin Astrocytoma (Cell Line: U251) [7]
Valrubicin + Sirolimus DCS9QAP Valrubicin Astrocytoma (Cell Line: SNB-19) [7]
Valrubicin + Sirolimus DC3N680 Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [7]
Valrubicin + Sirolimus DC3O4D8 Valrubicin Chronic myelogenous leukemia (Cell Line: K-562) [7]
Valrubicin + Sirolimus DCI7BXW Valrubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [7]
Valrubicin + Sirolimus DCOM3TF Valrubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [7]
Valrubicin + Sirolimus DCKN7DO Valrubicin Glioblastoma (Cell Line: SNB-75) [7]
Valrubicin + Sirolimus DCY1J5O Valrubicin Glioma (Cell Line: SF-295) [7]
Valrubicin + Sirolimus DCSZQOU Valrubicin Papillary renal cell carcinoma (Cell Line: ACHN) [7]
Valrubicin + Sirolimus DCEICOV Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [7]
Valrubicin + Sirolimus DC3P4R2 Valrubicin Renal cell carcinoma (Cell Line: UO-31) [7]
Valrubicin + Sirolimus DCBG1ER Valrubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Valrubicin + Sirolimus DCGUWQ6 Valrubicin Carcinoma (Cell Line: RXF 393) [8]
Valrubicin + Sirolimus DCBI0E8 Valrubicin Carcinoma (Cell Line: MCF7) [8]
Valrubicin + Sirolimus DCMSPH5 Valrubicin Colon adenocarcinoma (Cell Line: COLO 205) [8]
Valrubicin + Sirolimus DC9XMNP Valrubicin Invasive ductal carcinoma (Cell Line: T-47D) [8]
Valrubicin + Sirolimus DCOHGQX Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Valrubicin + Sirolimus DCDYF6O Valrubicin Adenocarcinoma (Cell Line: DU-145) [9]
Valrubicin + Sirolimus DCS96QI Valrubicin Adenocarcinoma (Cell Line: NCIH23) [9]
Valrubicin + Sirolimus DCA8N5T Valrubicin Adenocarcinoma (Cell Line: SW-620) [9]
Valrubicin + Sirolimus DCCCKIU Valrubicin Adenocarcinoma (Cell Line: HCC-2998) [9]
Valrubicin + Sirolimus DCJHR1L Valrubicin Amelanotic melanoma (Cell Line: M14) [9]
Valrubicin + Sirolimus DCF5UMD Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Valrubicin + Sirolimus DCNOQ8V Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Valrubicin + Sirolimus DCZFIAV Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Valrubicin + Sirolimus DCCFT8Y Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Valrubicin + Sirolimus DCIY6XO Valrubicin Large cell lung carcinoma (Cell Line: NCI-H460) [9]
Valrubicin + Sirolimus DC7SH0M Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [9]
Valrubicin + Sirolimus DC2MWYO Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [9]
Valrubicin + Sirolimus DCLHAUO Valrubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Valrubicin + Sirolimus DCG68W3 Valrubicin Malignant melanoma (Cell Line: UACC62) [9]
Valrubicin + Sirolimus DCVSLZL Valrubicin Melanoma (Cell Line: MALME-3M) [9]
Valrubicin + Sirolimus DC2QUWK Valrubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Valrubicin + Sirolimus DC164G2 Valrubicin Prostate carcinoma (Cell Line: PC-3) [9]
Vandetanib + Sirolimus DCSOXXS Vandetanib Colon carcinoma (Cell Line: KM12) [8]
Vandetanib + Sirolimus DCVBP3C Vandetanib Invasive ductal carcinoma (Cell Line: T-47D) [8]
Vandetanib + Sirolimus DCS7GZF Vandetanib Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Vandetanib + Sirolimus DC7OVAO Vandetanib Adenocarcinoma (Cell Line: A549) [9]
Vandetanib + Sirolimus DCEBND3 Vandetanib Adenocarcinoma (Cell Line: NCIH23) [9]
Vandetanib + Sirolimus DCX77QR Vandetanib Adenocarcinoma (Cell Line: HCT116) [9]
Vandetanib + Sirolimus DCS4XQS Vandetanib Adenocarcinoma (Cell Line: HCT-15) [9]
Vandetanib + Sirolimus DCKWWCI Vandetanib Adenocarcinoma (Cell Line: HT29) [9]
Vandetanib + Sirolimus DCAOUMQ Vandetanib Adenocarcinoma (Cell Line: SW-620) [9]
Vandetanib + Sirolimus DCG3ORA Vandetanib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Vandetanib + Sirolimus DCK8P1Y Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [9]
Vandetanib + Sirolimus DC00LIL Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Vandetanib + Sirolimus DC6KB2Z Vandetanib Clear cell renal cell carcinoma (Cell Line: A498) [9]
Vandetanib + Sirolimus DCI4Q9J Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Vandetanib + Sirolimus DCUFNZN Vandetanib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Vandetanib + Sirolimus DCR47OI Vandetanib Lung adenocarcinoma (Cell Line: HOP-62) [9]
Vandetanib + Sirolimus DC2VQW4 Vandetanib Lung adenocarcinoma (Cell Line: EKVX) [9]
Vandetanib + Sirolimus DC8NJBS Vandetanib Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Vandetanib + Sirolimus DCTJ0H2 Vandetanib Malignant melanoma (Cell Line: LOX IMVI) [9]
Vandetanib + Sirolimus DCZA1WV Vandetanib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Vandetanib + Sirolimus DCW08WB Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Vandetanib + Sirolimus DC7MSHR Vandetanib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Vandetanib + Sirolimus DCJLSD2 Vandetanib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Vemurafenib + Sirolimus DC3GK5T Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [8]
Vemurafenib + Sirolimus DC4EIN7 Vemurafenib Carcinoma (Cell Line: RXF 393) [8]
Vemurafenib + Sirolimus DCIUX4O Vemurafenib Colon adenocarcinoma (Cell Line: COLO 205) [8]
Vemurafenib + Sirolimus DCX6ZOG Vemurafenib Colon carcinoma (Cell Line: KM12) [8]
Vemurafenib + Sirolimus DCCKC4S Vemurafenib Invasive ductal carcinoma (Cell Line: T-47D) [8]
Vemurafenib + Sirolimus DC3FEP3 Vemurafenib Invasive ductal carcinoma (Cell Line: HS 578T) [8]
Vemurafenib + Sirolimus DCI4L77 Vemurafenib Amelanotic melanoma (Cell Line: M14) [9]
Vemurafenib + Sirolimus DC9GAAC Vemurafenib Amelanotic melanoma (Cell Line: MDA-MB-435) [9]
Vemurafenib + Sirolimus DCTACOE Vemurafenib Anaplastic large cell lymphoma (Cell Line: SR) [9]
Vemurafenib + Sirolimus DC15YFY Vemurafenib Astrocytoma (Cell Line: U251) [9]
Vemurafenib + Sirolimus DCB8G8P Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Vemurafenib + Sirolimus DC23FJP Vemurafenib Clear cell renal cell carcinoma (Cell Line: A498) [9]
Vemurafenib + Sirolimus DCCQXLI Vemurafenib Clear cell renal cell carcinoma (Cell Line: TK-10) [9]
Vemurafenib + Sirolimus DCM492V Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [9]
Vemurafenib + Sirolimus DCK6GE5 Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-28) [9]
Vemurafenib + Sirolimus DC3PF7Z Vemurafenib Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Vemurafenib + Sirolimus DCC1N6T Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [9]
Vemurafenib + Sirolimus DCNOFM3 Vemurafenib Melanoma (Cell Line: MALME-3M) [9]
Vemurafenib + Sirolimus DCOBAGD Vemurafenib Melanoma (Cell Line: UACC-257) [9]
Vemurafenib + Sirolimus DC59RVX Vemurafenib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Vemurafenib + Sirolimus DCUK71T Vemurafenib Papillary renal cell carcinoma (Cell Line: ACHN) [9]
Vemurafenib + Sirolimus DCRMUNX Vemurafenib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Vemurafenib + Sirolimus DC8TNUI Vemurafenib Renal cell carcinoma (Cell Line: UO-31) [9]
Vincristine + Sirolimus DCD5549 Vincristine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [7]
Vincristine + Sirolimus DCAJF42 Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [7]
Vincristine + Sirolimus DCLJEGR Vincristine Lung adenocarcinoma (Cell Line: NCI-H522) [7]
Vincristine + Sirolimus DCKKAGG Vincristine Malignant melanoma (Cell Line: LOX IMVI) [7]
Vincristine + Sirolimus DCCGXGX Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [7]
Vincristine + Sirolimus DC876GI Vincristine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [7]
Vincristine + Sirolimus DCY7N4B Vincristine Renal cell carcinoma (Cell Line: UO-31) [7]
Vinflunine + Sirolimus DC7UC1R Vinflunine Anaplastic large cell lymphoma (Cell Line: SR) [7]
Vinflunine + Sirolimus DCQ2VSX Vinflunine Astrocytoma (Cell Line: U251) [7]
Vinflunine + Sirolimus DCYQO7Q Vinflunine Clear cell renal cell carcinoma (Cell Line: A498) [7]
Vinflunine + Sirolimus DC8RPKY Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [9]
Vinflunine + Sirolimus DCLSE5Q Vinflunine Adenocarcinoma (Cell Line: A549) [9]
Vinflunine + Sirolimus DC23BFF Vinflunine Cutaneous melanoma (Cell Line: SK-MEL-5) [9]
Vinflunine + Sirolimus DC8Q252 Vinflunine Malignant melanoma (Cell Line: LOX IMVI) [9]
Vinflunine + Sirolimus DC73KYQ Vinflunine Prostate carcinoma (Cell Line: PC-3) [9]
Vismodegib + Sirolimus DC54XZG Vismodegib Carcinoma (Cell Line: RXF 393) [8]
Vismodegib + Sirolimus DCQ7T1L Vismodegib Carcinoma (Cell Line: MCF7) [8]
Vismodegib + Sirolimus DCKFRTB Vismodegib Colon carcinoma (Cell Line: KM12) [8]
Vismodegib + Sirolimus DCK8RYW Vismodegib Invasive ductal carcinoma (Cell Line: BT-549) [8]
Vismodegib + Sirolimus DCKKI8L Vismodegib Adenocarcinoma (Cell Line: DU-145) [9]
Vismodegib + Sirolimus DCY858Y Vismodegib Adenocarcinoma (Cell Line: OVCAR3) [9]
Vismodegib + Sirolimus DCXVV9F Vismodegib Adenocarcinoma (Cell Line: A549) [9]
Vismodegib + Sirolimus DCJ3E0E Vismodegib Adenocarcinoma (Cell Line: NCIH23) [9]
Vismodegib + Sirolimus DCQ80U6 Vismodegib Adenocarcinoma (Cell Line: HT29) [9]
Vismodegib + Sirolimus DCMGP08 Vismodegib Adenocarcinoma (Cell Line: HCT116) [9]
Vismodegib + Sirolimus DCHBN11 Vismodegib Adenocarcinoma (Cell Line: HCT-15) [9]
Vismodegib + Sirolimus DCDINLA Vismodegib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [9]
Vismodegib + Sirolimus DC6Q4IB Vismodegib Astrocytoma (Cell Line: U251) [9]
Vismodegib + Sirolimus DCP1IG9 Vismodegib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [9]
Vismodegib + Sirolimus DCNCXHY Vismodegib Chronic myelogenous leukemia (Cell Line: K-562) [9]
Vismodegib + Sirolimus DCDJ2XD Vismodegib Clear cell renal cell carcinoma (Cell Line: TK-10) [9]
Vismodegib + Sirolimus DCTIV37 Vismodegib Clear cell renal cell carcinoma (Cell Line: 786-0) [9]
Vismodegib + Sirolimus DCEP4SG Vismodegib Clear cell renal cell carcinoma (Cell Line: A498) [9]
Vismodegib + Sirolimus DCBXAGB Vismodegib Glioma (Cell Line: SF-539) [9]
Vismodegib + Sirolimus DCOJEUT Vismodegib Glioma (Cell Line: SF-295) [9]
Vismodegib + Sirolimus DCVM6JY Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [9]
Vismodegib + Sirolimus DC5FXYJ Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [9]
Vismodegib + Sirolimus DCSCH37 Vismodegib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [9]
Vismodegib + Sirolimus DC4FU3W Vismodegib Lung adenocarcinoma (Cell Line: MDA-MB-231) [9]
Vismodegib + Sirolimus DC64QRM Vismodegib Lung adenocarcinoma (Cell Line: EKVX) [9]
Vismodegib + Sirolimus DCHIKZE Vismodegib Lung adenocarcinoma (Cell Line: NCI-H522) [9]
Vismodegib + Sirolimus DC7CIVY Vismodegib Malignant melanoma (Cell Line: UACC62) [9]
Vismodegib + Sirolimus DCMB6G9 Vismodegib Malignant melanoma (Cell Line: LOX IMVI) [9]
Vismodegib + Sirolimus DC4LBG6 Vismodegib Melanoma (Cell Line: MALME-3M) [9]
Vismodegib + Sirolimus DCEYFU3 Vismodegib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [9]
Vismodegib + Sirolimus DC55ZN6 Vismodegib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [9]
Vismodegib + Sirolimus DCQP4T1 Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [9]
Vismodegib + Sirolimus DCWC4CW Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [9]
Vismodegib + Sirolimus DC8Q12C Vismodegib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [9]
Vismodegib + Sirolimus DCRO9QQ Vismodegib Prostate carcinoma (Cell Line: PC-3) [9]
Vismodegib + Sirolimus DCUP38V Vismodegib Renal cell carcinoma (Cell Line: UO-31) [9]
Vismodegib + Sirolimus DC4JQNC Vismodegib Renal cell carcinoma (Cell Line: SN12C) [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 687 DrugCom(s)
9 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Bortezomib + Sirolimus DC9EWP3 Bortezomib Autologous Hematopoietic Stem Cell Transplant Recipient [10]
Gold sodium thiomalate + Sirolimus DC7B2QS Gold sodium thiomalate Recurrent Non-small Cell Lung Cancer [11]
Mycophenolate mofetil + Sirolimus DC8HLX2 Mycophenolate mofetil Adult Hodgkin Lymphoma [12]
Sirolimus + Auranofin DCPB4V0 Auranofin Extensive Stage Small Cell Lung Carcinoma [13]
Sirolimus + Auranofin DCYDVDR Auranofin Recurrent Non-small Cell Lung Cancer [14]
Clofarabine + Sirolimus DCE284T Clofarabine Adult Acute Lymphoblastic Leukemia in Remission [15]
Cyclophosphamide + Sirolimus DC3CAQE Cyclophosphamide Acute Lymphoblastic Leukemia [16]
Mycophenolate mofetil + Sirolimus DC2TH11 Mycophenolate mofetil Acute Lymphoblastic Leukemia [16]
Sirolimus + Melphalan DCEOXNJ Melphalan Graft Versus Host Disease [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 Sirolimus FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 201578.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6031).
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 ClinicalTrials.gov (NCT04341675) Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia. U.S. National Institutes of Health.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
9 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
10 ClinicalTrials.gov (NCT01163357) Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
11 ClinicalTrials.gov (NCT01383668) Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer
12 ClinicalTrials.gov (NCT02728700) Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
13 ClinicalTrials.gov (NCT01737502) Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
14 ClinicalTrials.gov (NCT02126527) Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer
15 ClinicalTrials.gov (NCT01885689) Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
16 ClinicalTrials.gov (NCT03246906) Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
17 ClinicalTrials.gov (NCT00577278) A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan